Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4861889 | 0.91 | HRH2 (0.45) | HRH2HRH1L3MBTL1HDAC4HDAC1 | |
| SCHEMBL4864001 | 0.91 | SCN9A (0.52) | L3MBTL1SCN9ACYP3A4ACECTSL | |
| SCHEMBL4871841 | 0.86 | L3MBTL1 (0.47) | HRH2HRH1L3MBTL1HDAC4HDAC1 | |
| SCHEMBL4867141 | 0.82 | SCN9A (0.51) | SCN9ACYP3A4ACECTSL | |
| SCHEMBL4871937 | 0.79 | SCN9A (0.52) | L3MBTL1SCN9AACECTSL | |
| SCHEMBL18460227 | 0.76 | HDAC4 (0.68) | HRH2HRH1L3MBTL1HDAC4HDAC1 | |
| SCHEMBL9718207 | 0.76 | HDAC4 (0.68) | HRH2HRH1L3MBTL1HDAC4HDAC1 | |
| SCHEMBL4873372 | 0.75 | HDAC4 (0.44) | HDAC4HDAC1HDAC6SCN9AACE | |
| SCHEMBL25174673 | 0.75 | HDAC4 (0.58) | HRH2HRH1L3MBTL1HDAC4HDAC1 | |
| SCHEMBL29244834 | 0.75 | HDAC4 (0.58) | HRH2HRH1L3MBTL1HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439394-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2008-10-21 | — | — | US | claimed |
| US-20070117803-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-24 | — | — | US | claimed |
| EP-1751090-B1 | ACID DERIVATIVES OF SUBSTITUTED CYCLOHEXYL-1,4-DIAMINES | GRUENENTHAL GMBH (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-7439394-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20070117803-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117803-A1 | Cyclohexyl-1,4-diamine compounds | PKD1, DDC, DPYD | HRH2 181/4885HRH1 121/4885L3MBTL1 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.